Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Inclusion Criteria: - Informed consent obtained before any trial-related activities.Trial-related activities are any procedures that are carried out as part of the trial,including activities to determine suitability for the trial - Male or female, age equal toor above18 years at the time of signing informed consent - Diagnosed with type 2 diabetesmellitus (T2D) - HbA1c of 7.0-10.5% (53-91 mmol/mol, both inclusive) - Stable daily dose ofmetformin (equal to or above1500 mg or maximum tolerated dose as documented in the subjectmedical record and in compliance with current local label) for at least 90 days prior to

the day of screening Exclusion Criteria: - Known or suspected hypersensitivity to trialproduct(s) or related products - Previous participation in this trial. Participation isdefined as signed informed consent - Female who is pregnant, breast-feeding or intends tobecome pregnant or is of child-bearing potential and not using an adequate contraceptivemethod (adequate contraceptive measure as required by local regulation or practice) -Participation in any clinical trial of an approved or non-approved investigationalmedicinal product within 90 days prior to the day of screening - Any disorder which in theinvestigator's opinion might jeopardise subject's safety or compliance with the protocol -Subject with alanine aminotransferase (ALT) above 2.5 x upper normal limit (UNL) - Familyor personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.Family is defined as a first degree relative - History or presence of pancreatitis (acuteor chronic) - History of diabetic ketoacidosis (DKA) - Any of the following: myocardialinfarction (MI), stroke, hospitalization for unstable angina or transient ischaemic attackwithin the past 180 days prior to the day of screening - Subjects presently classified asbeing in New York Heart Association (NYHA) Class IV - Planned coronary, carotid orperipheral artery revascularisation known on the day of screening - Renal impairmentmeasured as eGFR below 60 ml/min/1.73 m^2 as defined by Kidney Disease Improving globaloutcomes (KDIGO 2012) classification using isotope dilution mass spectrometry (IDMS) forserum creatinine measured at screening - Treatment with any medication for the indicationof diabetes or obesity other than stated in the inclusion criteria within the past 90 daysprior to the day of screening. However, short term insulin treatment for a maximum of 14days prior to the day of screening is allowed - Proliferative retinopathy or maculopathyrequiring acute treatment. Verified by fundus photography or dilated fundoscopy performedwithin the past 90 days prior to randomisation - Presence or history of malignant neoplasmswithin the past 5 years prior to the day of screening. Basal and squamous cell skin cancerand any carcinoma in-situ is allowed - Medical history of diabetes-related lower limbamputations or signs of critical lower limb ischemia, (e.g. skin ulcer, osteomyelitis, organgrene) within the last 26 weeks prior to screening